Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zoledronic acid for prevention of cancer treatment-related bone loss in postmenopausal women receiving letrozole
2004-001369-17Phase 4Completed
- Sponsor
- Novartis
- Start
- Sep 2004
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of zoledronic acid in breast cancer and osteoporosis (2 arms), sponsored by Novartis. Primary endpoint: Primary: Percent change in lumbar spine (L2–L4) BMD at 12 months vs baseline. Started Sep 2004; status: completed.
02
Drugs
zoledronic acid
03
Conditions
breast cancerosteoporosis
Beyond the preview
Go deeper on 2004-001369-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-001369-17.